Airiver Medical

Airiver Medical is a clinical-stage medical device company developing minimally invasive technologies for the treatment of respiratory tract conditions. The company's lead product candidate is a Drug Coated Balloon platform targeting two primary indications: central airway stenosis (including subglottic, tracheal, and bronchial stenosis) and chronic rhinosinusitis (CRS). Central airway stenosis is a common complication following lung transplantation, prolonged intubation, and tracheostomy, affecting 7–18% of post-transplant patients. CRS is one of the most prevalent chronic conditions globally, affecting approximately 39+ million people in the U.S., with approximately half requiring surgical intervention. Airiver's Drug Coated Balloon is designed to provide sustained airway patency and potentially reduce the need for repeat procedures. The company has secured FDA Investigational Device Exemption (IDE) approval for pivotal clinical trials in both indications and is led by experienced medtech executives with backgrounds at Boston Scientific, Lutonix, Entellus Medical, and other leading device manufacturers.